The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer
The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer
复制标题
基质中肿瘤相关巨噬细胞的 M2 表型导致胰腺癌预后不良。
DOI：
10.1007/s13277-015-4741-z
复制
发表时间：
2016-07-01
期刊：
影响因子：
--
通讯作者：
Wang, Li-Wei
中科院分区：
文献类型：
--
作者：
Hu, Hai;Hang, Jun-Jie;Wang, Li-Wei
巨噬细胞在各种实体瘤的发生和发展中起着至关重要的作用。然而，它们在胰腺导管腺癌（PDAC）中的预后意义尚不清楚。本研究探讨巨噬细胞在PDAC中的分布模式及其与总生存期（OS）的可能关联。我们发现，在原发癌和配对的邻近正常组织中，巨噬细胞密度（由CD68和CD163免疫阳性鉴定，两者的p < 0.001）存在显著差异。癌变胰腺组织中巨噬细胞多位于间质而非胰岛（p = 0.032和p < 0.001）。我们还证明，高总巨噬细胞密度（以CD68免疫阳性为特征）与术前没有黄疸相关（p = 0.03），基质中高密度M2巨噬细胞（以CD163免疫阳性为特征）与位于胰腺尾部和体部的肿瘤密切相关（p = 0.04）。此外，高密度M2巨噬细胞浸润组的OS较低密度M2巨噬细胞浸润组短（p = 0.012）。此外，多因素分析显示M2巨噬细胞密集浸润间质是PDAC患者的独立预后因素（p = 0.02）。
Macrophages play a critical role in the initiation and progression of various solid tumors. However, their prognostic significance in pancreatic ductal adenocarcinoma (PDAC) is poorly understood. This study investigated the distribution patterns of macrophages in PDAC and possible association with the overall survival (OS). We found significant differences in macrophage density (identified by CD68 and CD163 immunopositivity; p < 0.001 for both) between primary cancer and paired adjacent normal tissues. Most macrophages in cancerous pancreatic tissues were located in the stroma rather than the islets (p = 0.032 and p < 0.001). We also demonstrated that a high total macrophage density (characterized by CD68 immunopositivity) correlated with an absence of jaundice before surgery (p = 0.03) and that a high density of M2 macrophages (characterized by CD163 immunopositivity) in the stroma strongly correlated with the tumors located in the tail and body of the pancreas (p = 0.04). In addition, OS was shorter in patients with high-density M2 macrophage infiltration than in those with low-density M2 macrophage infiltration (p = 0.012). Moreover, multivariate analysis revealed that dense M2 macrophage infiltration into the stroma was an independent prognostic factor for PDAC patients (p = 0.02).